Why Emerging Nicotine Products Are Creating New Questions for Insurers The nicotine marketplace has changed dramatically over the past decade. Traditionally, insurance underwriting relied on a relatively simple distinction: applicants were generally classified as either smokers or non-smokers. This approach reflected decades of evidence demonstrating the substantial health risks associated with combustible tobacco use and…

A New Direction in European Nicotine Policy Over the past decade, Europe has been at the centre of some of the world’s most significant debates on tobacco harm reduction. Products such as nicotine pouches, vaping products, and heated tobacco products emerged as alternatives to combustible cigarettes and were often discussed through the lens of risk…

New Research Offers Insights into Consumer Interest and Smoking Status As nicotine pouches continue to gain attention from regulators, researchers, and public health stakeholders, an important question remains: who is actually interested in using them? Much of the policy debate surrounding nicotine pouches focuses on potential risks, youth uptake, and regulatory controls. However, understanding who…

Examining the Scientific Case for Tobacco Harm Reduction As nicotine pouches become an increasingly prominent feature of nicotine policy discussions worldwide, debate often moves faster than the science itself. Regulators, public health stakeholders, researchers, and policymakers are grappling with important questions about risk, cessation, consumer behaviour, and appropriate regulatory frameworks. While long-term epidemiological evidence is…

As nicotine products continue to evolve, regulators and researchers face a recurring challenge: how can the performance of new products be evaluated efficiently, accurately, and consistently without relying exclusively on costly and time-consuming human clinical studies? A newly published study in Scientific Reports offers an interesting contribution to that discussion. Rather than focusing on consumer…

As governments consider how to regulate nicotine pouches, one model is becoming increasingly important: treating oral nicotine products not as general consumer goods, but as medicines, natural health products, poisons, or pharmaceutical-style nicotine replacement therapies. This approach is most clearly visible in Canada, where Zonnic has become the leading example of a nicotine pouch authorised…